# Nuclide record paper-hofman-lupsma-lancet-oncol-2018 (paper). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/key-papers/paper-hofman-lupsma-lancet-oncol-2018/>
  a schema:ScholarlyArticle ;
  nuclide:kind "paper" ;
  schema:identifier "paper-hofman-lupsma-lancet-oncol-2018" ;
  schema:name "LuPSMA trial: single-arm phase 2 study of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer"@en ;
  schema:description "In an early single-hospital study, most men with advanced prostate cancer who had run out of standard treatments saw their PSA fall by at least half after being treated with the radioactive drug lutetium-177 PSMA-617, with mild side effects."@en ;
  schema:url <https://nuclide.cc/key-papers/paper-hofman-lupsma-lancet-oncol-2018/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/29752180/> ;
  nuclide:tag "prostate cancer", "radioligand therapy", "phase 2" ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(18)30198-0> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, et al." ;
  nuclide:related <https://nuclide.cc/trials/therap/>, <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/technologies/lu177-radioligand-therapy/>, <https://nuclide.cc/technologies/psma-pet/>, <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/people/hofman-michael/>, <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/lu-177/> .